Cereno Scientific to Attend JPM Week and Biotech Showcase in San Francisco, US, on January 12-18, 2026

Cereno Scientific (Nasdaq First North: CRNO B) said it will attend JPM Week and the Biotech Showcase in San Francisco Jan. 12–18, 2026 to engage investors and potential partners as it advances its HDAC inhibitor pipeline; lead candidate CS1 is being pushed toward a global Phase IIb trial in pulmonary arterial hypertension after encouraging Phase IIa signals and an Expanded Access Program, while CS014 has moved from Phase I into Phase II and CS585 remains in preclinical development as a selective oral prostacyclin receptor agonist. Management highlighted growing external interest driven by these clinical milestones, making the upcoming conference an opportunity to secure strategic partnerships or capital ahead of potential value-inflection events tied to Phase II readouts and program advancement.

Analysis

Cereno Scientific announced it will attend JPM Week and the Biotech Showcase in San Francisco on January 12-18, 2026, with a dedicated presence at the Biotech Showcase on January 12-14, positioning management to engage investors and potential partners ahead of planned program milestones. CEO Sten R. Sörensen highlighted progression of the lead HDAC inhibitor CS1 toward a global Phase IIb trial in pulmonary arterial hypertension (PAH) and noted rising external interest following recent clinical progress.

The company reported that CS1 produced encouraging Phase IIa signals — including reverse vascular remodeling, improved right-heart function and enhanced patient quality of life — and is described as a well-tolerated oral therapy with an Expanded Access Program for prior participants. CS014 advanced from Phase I to Phase II on the basis of favorable safety/tolerability data, while CS585 remains in preclinical development as a selective oral prostacyclin (IP) receptor agonist with potential thrombotic benefits without added bleeding risk.

Participation at JPM Week creates a visible near-term catalyst for potential partnering or financing that could de-risk program funding ahead of Phase IIb initiation, consistent with the article’s mildly positive sentiment score (0.28) and modest market impact. Key risks remain classic biotech execution and regulatory timelines; the stock is listed on Nasdaq First North (CRNO B), implying varying liquidity and investor access considerations ahead of any deal or clinical readout.

Key Decisions for Investors

• Monitor JPM Week (Jan 12-18, 2026) for partnership or financing announcements and reassess position size if Cereno secures material collaboration or capital
• Positioning should be event-driven: consider limited exposure or options-based strategies ahead of CS1 Phase IIb initiation and CS014 Phase II milestones to capture upside while containing clinical execution risk
• Require transparency on Phase IIb design, endpoints and enrollment timelines before increasing exposure — if future data replicate Phase IIa signals on remodeling and right-heart function, upgrade conviction
• Given the company’s early-stage profile and modest market-impact signal (0.28), maintain risk controls such as size limits or stop-losses until partnering, financing, or positive Phase II data reduce binary outcome risk